Novartis AG (NVS) said Friday it agreed to buy private biotechnology firm Excellergy for as much as $2 billion in initial and milestone payments.
The proposed transaction includes an experimental early-stage IgE medication called Exl-111 designed to treat various allergic conditions, the company said.
The clinical therapy targets a specific biological driver of allergies to potentially provide faster symptom relief alongside more convenient dosing schedules, Novartis said.
The acquisition is expected to finalize during H2, pending standard regulatory approvals and closing conditions, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments